Disease Markers

Disease Markers / 1994 / Article

Open Access

Volume 12 |Article ID 179287 | https://doi.org/10.1155/1994/179287

A.-B. Halim, M. Barakat, A. M. El-Zayat, M. Daw, O. El-Ahmady, "Urinary β-HCG in Benign and Malignant Urinary Tract Diseases", Disease Markers, vol. 12, Article ID 179287, 7 pages, 1994. https://doi.org/10.1155/1994/179287

Urinary β-HCG in Benign and Malignant Urinary Tract Diseases

Received20 Jul 1994


Detectable leve ls of HCG have been reported in conditions other th an normal pregnancy, including threatened abortion, ectopic pregnancy, trophoblastic tumors, carcinomas of the stomach, liver, pancreas and breast as well as multiple myeloma and melanoma. The present study was conducted to estimate urinary β-HCG in bladder cancer and benign urinary tract disorders. 163 individuals were included, 68 with bladder cancer (60 males and 8 females), 64 with benign urinary tract diseases (55 males and 9 females) and 31 normal healthy controls (26 males and 5 females). Urinary β-HCG was estimated by the ELISA technique using the reagents supplied by DRG International Inc., Germany. Results of th e study revealed an overexpression of β-HCG in mali gnant and benign urinary tract diseases. 60.3% of the cancer patients and 29.7% of patients with benign diseases showed urinary β-HCG values above the upper limit of the control group (2mIU/ml ).

Copyright © 1994 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

 PDF Download Citation Citation
 Order printed copiesOrder

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.